Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2009 | 4 | 3 | 310-314

Article title

The effects of oxcarbazepine treatment on vitamin B12 and folate levels, thyroid functions, sex hormones, and bone mineral density in epileptic patients


Title variants

Languages of publication



The aim of this study was to evaluate vitamin B12 and folate levels, thyroid functions, sex hormones and bone mineral density in idiopathic epileptic patients taking oxcarbazepine as monotherapy. Newly diagnosed pediatric patients with idiopathic partial epilepsy taking oxcarbazepine (OXC) as monotherapy were enrolled in this study. The pre-treatment and 6 months post-treatment values of vitamin B12, folate, thyroid functions, sex hormones, and bone mineral density (BMD) were obtained from all patients. A total of 32 patients (22 (68.8%) males and 10 (31.2%) females) were included in this study. The mean age was 7.4 ± 3.2 years (range: 2–14 years). There were no significant differences between the pre-treatment and 6 months post-treatment values of vitamin B12, folate, thyroid functions, sex hormones, and BMD. However, the 6 month post-treatment sex hormone binding globulin (SHBG) values (159.92 ± 48.14 nmol/L) were significantly higher than the pre-treatment values (137.88 ± 43.12 nmol/L) (p=0.009). We found that OCX treatment in children did not have an effect on serum folate and vitamin B12 levels, thyroid functions, sex hormones and BMD but caused increased SHBG. Over time, the increase in serum SHBG levels may lead to diminished bioactivity of sex steroids, and thus to reduced fertility. The further studies are needed to demonstrate the clinical importance of increased SHBG levels.










Physical description


1 - 9 - 2009
3 - 7 - 2009


  • Gulhane Military Medical Academy Department of Pediatric Neurology, 06018, Etlik, Ankara, Turkey
  • Gulhane Military Medical Academy Department of Pediatric Neurology, 06018, Etlik, Ankara, Turkey
  • Gulhane Military Medical Academy Department of Pediatric Neurology, 06018, Etlik, Ankara, Turkey
  • Gulhane Military Medical Academy Department of Pediatric Neurology, 06018, Etlik, Ankara, Turkey
  • Gulhane Military Medical Academy Department of Pediatric Neurology, 06018, Etlik, Ankara, Turkey


  • [1] Karabiber H., Sonmezgoz E., Ozerol E., Yakinci C., Otlu B., Yologlu S., Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Develop., 2003, 25, 113–115 http://dx.doi.org/10.1016/S0387-7604(02)00163-8[Crossref]
  • [2] Ueland P.M., Refsum H., Beresford S.A.A., Vollset S.E., The controversy over homocysteine and cardiovascular risk. Am. J. Clin. Nutr., 2000, 72, 324–332
  • [3] Yoo J.H., Hong S.B., A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism, 1999, 48, 1047–1051 http://dx.doi.org/10.1016/S0026-0495(99)90204-4[Crossref]
  • [4] Apeland T., Mansoor M.A., Pentieva K., McNulty H., Seljeflot I., Strandjord R.E., The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs. Epilepsy Res., 2002, 51, 237–247 http://dx.doi.org/10.1016/S0920-1211(02)00153-5[Crossref]
  • [5] Apeland T., Mansoor M.A., Strandjord R.E., Vefring H., Kristensen O., Folate, homocysteine and methionine loading in patients on carbamazepine. Acta Neurol. Scand., 2001, 103, 294–299 http://dx.doi.org/10.1034/j.1600-0404.2001.103005294.x[Crossref]
  • [6] Hendel J., Dam M., Gram L., The effects of carbamazepine and valproate on folate metabolism in man. Acta Neurol. Scand., 1984, 69, 226–231 http://dx.doi.org/10.1111/j.1600-0404.1984.tb07805.x[Crossref]
  • [7] Verotti A., Basciani F., Morresi S., Morgese G., Chiarelli F., Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatric Neurol., 2001, 25, 43–46 http://dx.doi.org/10.1016/S0887-8994(01)00279-X[Crossref]
  • [8] Leena K.V., Kirsi M., Johanna R., Mikael K., Arto J.P., Vilho V.M., et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproat monotherapy and after withdrawal of medication. Epilpesia, 2004, 45, 197–203 http://dx.doi.org/10.1111/j.0013-9580.2004.26003.x[Crossref]
  • [9] Isojarvi J.I.T., Pakarinen A.J., Ylipalosaari P.J., Myllyla V.V., Serum hormones in male epileptic patients receiving anticonvulsant medication. Pediatric Neurol., 1990, 47, 670–676
  • [10] Kirsi M., Paivi T., Arto J.P., Markku P., Jouko I.T.I., Leena K.V., Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsia, 2004, 45, 769–776 http://dx.doi.org/10.1111/j.0013-9580.2004.04604.x[Crossref]
  • [11] Johanna R., Leena V., Mikeal K., Peter L., Jouko I.T.İ., The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics, 1999, 103, 588–593 http://dx.doi.org/10.1542/peds.103.3.588[Crossref]
  • [12] Alison M.P., Lucia S.O., Martha J.M., Edith F., Stanley R.R., Elisabeth S., Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav., 2003, 4, 169–174 http://dx.doi.org/10.1016/S1525-5050(03)00036-2[Crossref]
  • [13] Imran I.A., Gregory L.B., John R.G., Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav., 2004, 5, 296–300 http://dx.doi.org/10.1016/j.yebeh.2004.02.005[Crossref]
  • [14] Kulak C.A.M., Borba V.Z.C., Bilezikian J.P., Silvado C.E., Paola de L., Boguszewski C.L., Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arg. Neuropsiquiatr., 2000, 62, 940–948
  • [15] Filardi S., Guerreiro C.A.M., Neto J.F.M., Bone mineral density, vitamin D and anticonvulsant therapy. Arg. Neuropsiquatr., 2000, 58, 616–620 [Crossref]
  • [16] Akin R., Okutan V., Sarici S.U., Altunbas A., Gokçay E., Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr. Neurol., 1998, 19, 129–131 http://dx.doi.org/10.1016/S0887-8994(98)00039-3[Crossref]
  • [17] Tamura T., Aiso K., Johnston K.E., Black L., Faught E., Homocysteine, folate, vitamin B12 and vitamin B6 in patients receiving antiepileptic drug monotherapy. Epilepsy Res., 2000, 40, 7–15 http://dx.doi.org/10.1016/S0920-1211(00)00101-7[Crossref]
  • [18] Porcharuniti N., Lewis CA., Plasma homocysteine, folate and vitamine B-12 concentrations and risk for early onset coronary disease. Am. J. Clin. Nutr., 1994, 59, 940–948
  • [19] Dastur D., Dave U., Effect of prolonged anticonvulsant medication in epileptic patients: Serum lipids, vitamin B6, B12 and folic acid, proteins and fine structure of liver. Epilepsia, 1987, 28, 147–159 http://dx.doi.org/10.1111/j.1528-1157.1987.tb03641.x[Crossref]
  • [20] Krause K.H., Bonjour J.P., Berlit P., Kynast G., Schmidt-Gayk H., Schellenberg B., Effect of long-term treatment with antiepileptic drugs on the vitamin status. Drug. Nutr. Interact., 1988, 5, 317–343
  • [21] Reynold’s E., Chanarin I., Milner G., Matthews D., Anticonvulsant therapy folic acid and vitamin B12 metabolism and mental symptoms. Epilepsia, 1966, 7, 261–270 http://dx.doi.org/10.1111/j.1528-1157.1966.tb03806.x[Crossref]
  • [22] Cansu A., Serdaroglu A., Camurdan O., Hirfanoglu T., Bideci A., Gucuyener K., The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia, 2006, 47, 1855–1859 http://dx.doi.org/10.1111/j.1528-1167.2006.00821.x[Crossref]
  • [23] Cramer J.A., Jones E.E., Reproductive function in epilepsy. Epilepsia, 1991, 32, 19–26 http://dx.doi.org/10.1111/j.1528-1157.1991.tb05887.x[Crossref]
  • [24] Eiris-Punal J., Del-Rio Garma M., Del-Rio Garma M.C., Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia, 1999, 40, 1761–1766 http://dx.doi.org/10.1111/j.1528-1157.1999.tb01595.x[Crossref]
  • [25] Caksen H., Dulger H., Cesur Y., Atas B., Tuncer O., Odabas D., Evaluation of thyroid and parathyroid functions in children receiving long-term carbamazepine therapy. Int. J. Neurosci., 2003, 113, 1213–1217 http://dx.doi.org/10.1080/00207450390232300[Crossref]
  • [26] Vainionpaa L.K., Rattya J., Knip M., Valproateinduced hyperandrogenism during pubertal maturation in girls with epilepsy. Pediatric Neurol., 1999, 45, 444–450
  • [27] Ramsay R.E., Slater J.D., Effects of antiepileptic drugs on hormones. Epilepsia, 1991, 32, 60–67 http://dx.doi.org/10.1111/j.1528-1157.1991.tb05894.x[Crossref]
  • [28] Isojarvi J.I., Taubll E., Herzog A.G., Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs, 2005, 19, 207–223 http://dx.doi.org/10.2165/00023210-200519030-00003[Crossref]
  • [29] Fenwick P.B.C., Toone B.K., Wheeler M.J., Nanje M.N., Grant R., Brown D., Sexual behaviour in a centre for epilepsy. Acta Neurol. Scand., 1985, 71, 428–435 http://dx.doi.org/10.1111/j.1600-0404.1985.tb03225.x[Crossref]
  • [30] Vestergaard P., Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol. Scand., 2005, 112, 277–286 http://dx.doi.org/10.1111/j.1600-0404.2005.00474.x[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.